Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib for recurrence prevention after primary hepatocellular carcinoma resection in high-risk patients
ChiCTR1900027953Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: disease-free survival. Started Jan 2020; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900027953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027953.